Neuraxis (NRXS) Other Accumulated Expenses (2022 - 2025)
Neuraxis (NRXS) posted Other Accumulated Expenses of $108191.0 for Q4 2025, up 186.45% sequentially from $37770.0 in Q3 2025, and up 270.85% YoY from $29174.0 in Q4 2024.
Neuraxis (NRXS) Other Accumulated Expenses (2022 - 2025) Analysis & Trends
Neuraxis has reported Other Accumulated Expenses for 4 years, with the latest figure at $108191.0 in Q4 2025.
- Quarterly Other Accumulated Expenses rose 270.85% year-over-year to $108191.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $108191.0 (up 270.85% YoY) and the FY2025 annual result came in at $108191.0, up 270.85% from the prior year.
- Other Accumulated Expenses rose to $108191.0 in Q4 2025 per NRXS's latest filing, from $37770.0 in the prior quarter.
- Over five years, Other Accumulated Expenses peaked at $155351.0 in Q1 2025 and troughed at $963.0 in Q4 2023.
- A 4-year average of $50981.6 and a median of $39515.5 in 2023 frame the typical range for Other Accumulated Expenses.
- The sharpest annual moves came in 2023 and 2024: Other Accumulated Expenses plunged 97.12% in 2023, then jumped 4267.7% in 2024.
- Over 4 years, Other Accumulated Expenses stood at $33395.0 in 2022, then slumped by 97.12% to $963.0 in 2023, then soared by 2929.49% to $29174.0 in 2024, then jumped by 270.85% to $108191.0 in 2025.
- According to Business Quant data, Other Accumulated Expenses over the past three periods registered $108191.0, $37770.0, and $63996.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Neuraxis | 74.54 Mn | 66.21 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 108,191.00 |
| Sep 30, 2025 | 37,770.00 |
| Jun 30, 2025 | 63,996.00 |
| Mar 31, 2025 | 155,351.00 |
| Dec 31, 2024 | 29,174.00 |
| Sep 30, 2024 | 56,387.00 |
| Jun 30, 2024 | 48,247.00 |
| Mar 31, 2024 | 35,753.00 |
| Dec 31, 2023 | 963.00 |
| Sep 30, 2023 | 1,291.00 |
| Jun 30, 2023 | 41,261.00 |
| Dec 31, 2022 | 33,395.00 |